Status:
COMPLETED
A Study to Compare the Pharmacokinetics and Safety of Optivate® and Haemate P® in Patients With Von Willebrand Disease.
Lead Sponsor:
Bio Products Laboratory
Conditions:
vonWillebrand's Disease
Eligibility:
All Genders
12+ years
Phase:
PHASE2
Brief Summary
The main objectives of the study were * to compare the pharmacokinetics (PK) of Optivate® and Haemate P® in various types of vonWillebrand disease (VWD) using the results from the VWF: RCo, VWF:Ag, V...
Eligibility Criteria
Inclusion
- Previously treated subjects of at least 12 years of age, with any type of VWD were eligible for entry into this study.
Exclusion
- \-
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT02250508
Start Date
December 1 2004
Last Update
February 15 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hematology Dept., Sackler School of Medicine, Tel Aviv University
Tel Aviv, Israel